{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-223282","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.741349+00:00","generated_at":"2026-05-31T02:32:02.368546+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M","bullets":["BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.","BioAtla eligible for up to $133.5M total, including $15M upfront/near-term milestones and $118.5M in future milestones plus tiered royalties.","BioAtla enters Global Transaction Agreement with Himalaya Therapeutics, consenting to license and sharing a mid-teens percentage of upfront/milestone payments.","Context may terminate at will; BioAtla may terminate if Context halts development for 8 consecutive quarters.","BioAtla agrees to refrain from competitive activities regarding Nectin-4 bispecific/multi-specific antibodies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-223282","json":"https://secwatch.observer/filing/0001193125-24-223282.json","markdown":"https://secwatch.observer/filing/0001193125-24-223282.md","text":"https://secwatch.observer/filing/0001193125-24-223282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/0001193125-24-223282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/d845616d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:32:02.368546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}